This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Geron (GERN) Up 10.6% Since Its Last Earnings Report?
by Zacks Equity Research
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Geron Stock Surged More Than 90% in 6 Months
by Zacks Equity Research
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.
Geron (GERN) Q4 Loss Flat Y/Y, Revenues Surge, Shares Up
by Zacks Equity Research
Geron (GERN) misses earnings and sales estimates in Q4. However, revenues almost double year over year. Imetelstat remains in focus.
Geron (GERN) in Focus: Stock Moves 10.8% Higher
by Zacks Equity Research
Geron (GERN) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
J&J's (JNJ) Erdafitinib Gets Breakthrough Therapy Status
by Zacks Equity Research
The breakthrough therapy designation for J&J's (JNJ) erdafitinib was based on efficacy findings from a phase II study, evaluating it in advanced urothelial cancer.
What's in the Cards for Geron (GERN) This Earnings Season?
by Zacks Equity Research
With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q4 release.
Geron (GERN) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Geron's (GERN) loss per share in the third quarter was narrower than expected. However, revenues missed estimates. Imetelstat remains in focus.
Geron (GERN) in Focus: Stock Moves 9.2% Higher
by Zacks Equity Research
Geron (GERN) saw its shares rise over 9% on the day after the company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its experimental blood-cancer medicine, imetelstat.
What's in the Cards for Geron (GERN) this Earnings Season?
by Zacks Equity Research
With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q3 release.
Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern
by Zacks Equity Research
Geron Corporation's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.
Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up
by Zacks Equity Research
Geron Corporation (GERN) reported narrower-than-expected loss in Q2 while sales missed estimates. Shares were up in after-hours trading.
What's in the Cards for Geron (GERN) this Earnings Season?
by Zacks Equity Research
Investors will be looking at Geron's progress with its hematologic myeloid malignancies pipeline candidate, Imetelstat.
Why Geron (GERN) Might Be a Diamond in the Rough
by Zacks Equity Research
Geron (GERN) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.
Geron Stock Up Almost 40% So Far This Year After '16 Decline
by Zacks Equity Research
Geron Corporation's (GERN) shares have risen 38.7% this year so far, outperforming the Zacks classified Medical - Biomedical and Genetics industry, which rose 5.6%. This comes after a decline of more than 57% in 2016.
5 Biomedical Stocks That Are Expected To Surge
by Jeffrey Hymen
With the promise of regulatory reform on the horizon, investors have been excited about the biomedical space throughout the year. If you want to add some to your portfolio, check out these 5 biomedical stocks that are primed to skyrocket here.
Here's Why Geron (GERN) is a Good Stock to Invest in Now
by Zacks Equity Research
Geron Corporation (GERN) is developing anti-cancer therapies based on telomerase inhibitors.
The Zacks Analyst Blog Highlights: Cambrex, Geron, Anavex Life Sciences and Histogenics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cambrex, Geron, Anavex Life Sciences and Histogenics
Fresh Capital to Be Injected into Biotech Stocks: 5 Must-Buys
by Tirthankar Chakraborty
IBB surged 17% since Trump's win but is still down 23% from its all-time intraday high scaled in the July of 2015.
Mallinckrodt Initiates Amyotrophic Lateral Sclerosis Study
by Zacks Equity Research
Mallinckrodt plc (MNK) announced that it has enrolled the first patient in its phase IIB study, PENNANT.
Omeros (OMER) Hits New 52-Week High on Positive FDA Decision
by Zacks Equity Research
Omeros Corporation (OMER) shares hit a new 52-week high of $22.80 on Thursday before eventually closing at $22.15.
Geron (GERN) Up 3.1% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Geron (GERN) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Geron Corp (GERN) Worth a Look: Stock Adds 7% in Session
by Zacks Equity Research
Geron Corporation (GERN) shares rose over 7% in the last trading session.
Geron (GERN) Q1 Loss In Line, Focus Remains on Imetelstat
by Zacks Equity Research
Geron Corporation (GERN) reported a loss of 5 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate. In the year-ago quarter.
Geron (GERN) Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Geron Corporation (GERN) is expected to report first-quarter 2017 results next week
Will Geron (GERN) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Geron Corporation (GERN).